Shameem Mahmood
Overview
Explore the profile of Shameem Mahmood including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
1094
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ravichandran S, Hall A, Jenner M, Garg M, Kishore B, Lachmann H, et al.
Amyloid
. 2023 May;
30(3):290-296.
PMID: 37216268
Introduction: Proteasome inhibitors are the backbone of AL amyloidosis treatment - bortezomib being most widely used. Carfilzomib is a proteasome inhibitor licenced to treat multiple myeloma; autonomic and peripheral neuropathy...
12.
Rauf M, Hawkins P, Cappelli F, Perfetto F, Zampieri M, Argiro A, et al.
Eur Heart J
. 2023 Mar;
44(24):2187-2198.
PMID: 36946431
Aims: To perform evaluation of widely embraced bone scintigraphy-based non-biopsy diagnostic criteria (NBDC) for ATTR amyloid cardiomyopathy (ATTR-CM) in clinical practice, and to refine serum free light chain (sFLC) ratio...
13.
Cohen O, Rendas-Baum R, McCausland K, Foard D, Manwani R, Ravichandran S, et al.
Br J Haematol
. 2023 Jan;
201(3):422-431.
PMID: 36709756
This study reports health-related quality of life (HRQL) among newly-diagnosed immunoglobulin light-chain (AL) patients (n = 914) treated with a bortezomib-based regimen and its association with response depth and survival....
14.
Martinez-Naharro A, Patel R, Kotecha T, Karia N, Ioannou A, Petrie A, et al.
Eur Heart J
. 2022 Oct;
43(45):4722-4735.
PMID: 36239754
Aims: To assess the ability of cardiovascular magnetic resonance (CMR) to (i) measure changes in response to chemotherapy; (ii) assess the correlation between haematological response and changes in extracellular volume...
15.
Ravichandran S, Law S, Mahmood S, Wisniowski B, Foard D, Fontana M, et al.
Am J Hematol
. 2022 Sep;
97(12):E444-E446.
PMID: 36088630
No abstract available.
16.
Khwaja J, Bomsztyk J, Mahmood S, Wisniowski B, Shah R, Tailor A, et al.
Blood Cancer J
. 2022 Sep;
12(9):128.
PMID: 36064540
No abstract available.
17.
Asher S, Kazantzi A, Dekaj F, Steventon L, Khatun A, Ainley L, et al.
Haematologica
. 2022 Aug;
107(12):2961-2965.
PMID: 36005557
No abstract available.
18.
Cohen O, Sathyanath A, Petrie A, Ravichandran S, Law S, Manwani R, et al.
Heart
. 2022 Jun;
108(20):1616-1622.
PMID: 35764371
Objectives: In AL amyloidosis, organ response assessment is based on surrogates (eg, cardiac biomarkers). An objective functional test, such as the 6 min walk test (6MWT), capturing overall clinical improvement,...
19.
Howells L, Chan W, Sanchez E, Horder J, Newrick F, Marfil J, et al.
Leuk Lymphoma
. 2022 May;
63(10):2489-2493.
PMID: 35570744
No abstract available.
20.
Ravichandran S, Mahmood S, Wisniowski B, Sachchithanantham S, Popat R, Lachmann H, et al.
Br J Haematol
. 2022 May;
198(2):328-332.
PMID: 35509237
Depth of response is the critical determinant of prognosis in amyloid light-chain (AL) amyloidosis. Here, we aim to identify patients who are unlikely to improve response based on analysis of...